drugset

drugset / Trial / NCT05327270

Non-randomized, Open-label Study of Intralesional Nivolumab for High Risk Oral Premalignant Lesions

NCT05327270 ↗

Phase 1 Active not recruiting 18 enrolled M.D. Anderson Cancer Center

NaSingle-groupOpen-labelTreatment

Summary

To characterize the safety and tolerability of nivolumab injected intralesionally in patients with high-risk oral premalignant lesions.

Timeline

Start: 2022-09-13
Primary completion: 2027-02-02
Completion: 2027-02-02

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Nivolumab	Monoclonal antibody	—	Other

Indications